Medtronic Begins Pediatric Clinical Trial of Spinal Tether for Treatment of Scoliosis

As First Patient Is Enrolled in the Clinical Trial of Braive™ Growth Modulation System, Study Reaffirms Medtronic's Commitment to Pediatric Spine Innovation

- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced that it has enrolled its first patient and completed the first surgical procedure in its BRAIVE™ IDE study which will evaluate the safety and effectiveness of the Braive™ growth modulation system for treatment of progressive  Adolescent Idiopathic Scoliosis (AIS). The first patient was recruited by The Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom . The device is Medtronic's latest innovation in the pediatric spine category, and the study's initiation reaffirms the company's commitment to continued innovation for pediatric patients.

About 4% of children globally have scoliosis, making it one of the most common pediatric orthopedic deformities. 1 It occurs when the vertebrae twist or rotate, causing the spine to curve into a "C" or "S" shape, rather than a straight line. It typically occurs in children and impacts girls more often than boys. Standard treatment options may include braces or spinal fusion surgery. According to the National Scoliosis Foundation, an estimated 30,000 children a year receive a brace to treat their condition, while 38,000 patients are treated with spinal fusion. 2 While successful in correcting the spine's curve, spinal fusion causes vertebrae to fuse together into a single bone, which stops growth in that area of the spine.

The Braive growth modulation system uses a braid secured to the spine with screws to slow growth on the curved side of the spine, while allowing growth to continue on the other side. The BRAIVE IDE study will evaluate whether the system is safe and effective in correcting the spine's curve in patients with juvenile or adolescent idiopathic scoliosis. The prospective, multi-center study will enroll patients in the United States , Canada , and the United Kingdom .

"There continues to be an unmet need for medical devices specifically tailored to pediatric patients," said Andrew Bowey , consultant orthopedic surgeon, Newcastle Hospitals, and BRAIVE IDE study principal investigator. "The Braive system is designed to correct scoliosis while allowing the spine to continue to grow, which is important for adolescents who are experiencing their most significant period of growth. I'm excited about its potential and the ability to bring this study to my patients who may benefit."

"Launching the BRAIVE IDE study is our latest step in bringing life-changing technologies to pediatric patients," said Carlton Weatherby , vice president and general manager of Spine & Biologics within the Cranial & Spinal Technologies business, which is part of the Neuroscience Portfolio at Medtronic. "As image guidance and navigation compatibilities extend further into additional spinal implant systems indicated for pediatric populations, they are coupled with a rapid cadence of transformative implant innovation. This uniquely positions us to offer the most comprehensive and integrated ecosystem of procedural solutions to pediatric spine surgeons driving meaningful improvements in clinical outcomes for young patients."

To learn more about Medtronic Spine & Biologics, visit Medtronic.com/SpineSurgery .

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

References

  1. Julien C, Gorman KF, et al. "Towards a comprehensive diagnostic assay for scoliosis." Per Med. 2013 Jan;10(1):97-103. doi: 10.2217/pme.12.117.
  2. "Scoliosis." American Association of Neurological Surgeons. https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Scoliosis . Accessed Aug. 30, 2021 .

Contacts:




Donna Marquard

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-526-6248

+1-763-505-4626

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-begins-pediatric-clinical-trial-of-spinal-tether-for-treatment-of-scoliosis-301382107.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×